What Wegovy does to belly fat: the evidence explained

What the STEP trials actually measured about abdominal and visceral fat

The headline figure from STEP 1 is the 15% average body-weight loss. Less discussed, but clinically significant, is what happened to body composition inside that number. Participants showed reductions in waist circumference alongside total weight loss, reflecting a fall in abdominal fat mass. Visceral adipose tissue, the fat packed around the liver, pancreas and intestines, is metabolically active in ways subcutaneous fat is not, so its reduction carries real health implications beyond trouser size.

Semaglutide works as a GLP-1 receptor agonist, slowing gastric emptying and reducing appetite signals in the brain. The body draws on fat stores as calorie intake falls. It does not selectively burn belly fat first; no medicine does. What the evidence shows is that visceral fat falls proportionally, and sometimes slightly more than average, as overall weight comes down. The NHS medicines information for semaglutide describes the mechanism clearly and is worth reading alongside any clinical consultation.

Wegovy 2.4mg was the standard licensed maintenance dose for UK adults. Since January 2026, a higher 7.2mg maintenance dose has also been approved by the MHRA, with trials at that dose reporting around 20.7% average weight loss over 72 weeks — narrowing the gap with tirzepatide. The direction of travel on abdominal fat measures follows the same proportional pattern.

Why belly fat in particular attracts attention on semaglutide treatment

People often ask about the wegovy belly specifically because visceral fat is linked to a cluster of health risks: insulin resistance, raised triglycerides, elevated blood pressure and cardiovascular disease. Losing it isn't purely cosmetic. Clinical guidelines recognise this, which partly explains why Wegovy's licensed indications include adults with weight-related conditions as well as those with a BMI of 30 or above without comorbidities.

In practice, people notice changes in waist measurements before the scales have moved much. That reflects fat redistribution as lean mass is preserved to a greater degree when protein intake stays adequate alongside treatment. It is also why clinical teams focus on waist circumference and health markers, not just weight loss percentages, when reviewing progress.

For a closer look at the specific data on semaglutide and abdominal fat, the semaglutide and belly fat page covers the compositional studies in more detail. Understanding both the broader weight data and the abdominal-specific findings gives a clearer picture than either alone.

Eligibility, realistic expectations and what treatment involves

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses the full picture; BMI alone doesn't determine suitability.

Treatment starts at 0.25mg and titrates upward under clinical supervision, typically in four-week steps. Most people reach the 2.4mg maintenance dose after around 16 weeks, though the pace is adjusted to tolerance. The most common side effects are gastrointestinal (nausea, loose stools, constipation, reflux) and tend to be most noticeable around dose increases before settling. If you are wondering whether Wegovy helps lose belly fat, the evidence is encouraging, but it sits inside a broader commitment to treatment that includes dietary changes and increased activity alongside the medicine.

On the NHS, Wegovy is available via specialist weight management services under NICE guidance, and waiting lists are often substantial. For context on what private treatment currently costs, the Wegovy pricing page covers what's typically included in a legitimate private prescription service. One thing worth noting: when your treatment is dispatched through a regulated pharmacy, you'll get DPD tracking to your door in plain, unbranded packaging — a small but reassuring detail for anyone nervous about discretion.

When to seek medical advice during treatment

GLP-1 medicines including semaglutide carry a small but recognised risk of acute pancreatitis. The MHRA highlighted this in a Drug Safety Update in January 2026: severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention rather than waiting for your next review. Separately, symptoms of dehydration from prolonged vomiting or diarrhoea should be taken seriously and medical advice sought early.

Other reasons to contact a clinician promptly include signs of an allergic reaction, significant mood changes or any new symptoms that concern you. You can report suspected side effects directly to the MHRA through the Yellow Card scheme, which exists precisely because Wegovy carries a Black Triangle and is still accumulating post-market safety data. Routine reviews before every repeat prescription exist to catch these things, not as a formality, but as a genuine clinical checkpoint.

If you want to discuss whether Wegovy is appropriate for your situation, our clinical team is available seven days a week. Speak to our prescribers through a free consultation, reviewed the same day by a real clinician, or read more about Wegovy and belly fat if that is your primary concern going into the conversation.